Anti-Mouse Jagged 2 – Purified in vivo PLATINUM™ Functional Grade

The most common in vivo application of clone HMJ2-1 in mice is for functional studies targeting the Jagged2 (JAG2) ligand of the Notch signaling pathway, especially in contexts investigating immune regulation and T cell biology. HMJ2-1 is primarily used for:

• Blocking or modulating Notch/Jagged2 signaling to study its physiological and pathological roles in mice, including immune cell fate and function.
• Agonist activity, where HMJ2-1 can promote Treg (regulatory T cell) differentiation and activate canonical Notch signaling pathways via RBP-Jk. This has been used to investigate immune tolerance, autoimmunity, and possibly graft-versus-host disease mechanisms.
• Flow cytometry-based detection of Jagged2 expression on mouse cells for immunophenotyping.
• ELISA to detect and quantify Jagged2 protein in mouse tissues or cells.

Key points and context:

• Functional-grade HMJ2-1 antibody is available from several vendors, specifically marketed and validated for in vivo use in mice.
• It is not used as a therapeutic in animals or humans, but as a research tool to manipulate or detect Jagged2 for mechanistic immunology studies.
• Agonist (stimulatory) effects of HMJ2-1 in vivo have been demonstrated, notably in studies examining Treg induction and modulation of immune responses (e.g., Elyaman et al., Immunity, 2012).
• Blocking experiments using HMJ2-1 typically aim to dissect Notch pathway contributions to inflammation, tolerance, and cell differentiation.

Less common applications:

• While most in vivo work focuses on immunology and Notch function, HMJ2-1 may also be used to explore developmental biology, as Notch signaling is essential in tissue differentiation.

There is no evidence from the search results of direct therapeutic use or toxicity studies of HMJ2-1 in mice or other species. Its use is restricted to research, often in immunocompetent mice, transgenics, or disease models interested in Jagged2/Notch modulation.

Commonly used antibodies or proteins in the literature alongside HMJ2-1 (an anti-Jagged2 monoclonal antibody) often target components of the Notch signaling pathway or related surface markers, depending on the research context.

Key co-used antibodies and proteins include:

• Notch Receptors (Notch1, Notch2, Notch3, Notch4): As Jagged2 is a ligand for Notch receptors, studies commonly use antibodies detecting these receptors to investigate signaling interactions or pathway activation status.
• Other Notch Ligands: Antibodies against other Notch ligands such as Jagged1 or Delta-like ligands (DLL1, DLL4) are often used to compare expression patterns and functional overlap or specificity with Jagged2 (the target of HMJ2-1).
• T cell and Immune Markers:
  • CD4, CD8, CD25, FoxP3: In immunology, flow cytometric analysis of T cell subsets and regulatory T cells is frequently performed concurrently with Jagged2/HMJ2-1 staining, especially in studies of Treg differentiation.
• Intracellular Signaling Proteins:
  • RBP-Jκ: Since RBP-Jκ is the canonical nuclear effector of Notch signaling, antibodies against RBP-Jκ or related transcriptional regulators are sometimes used to assess downstream pathway activation.
• Isotype Controls: IgG1 isotype control antibodies are routinely included in flow cytometry or immunohistochemistry for comparison and specificity control.
• Agonist/Antagonist Proteins: Soluble forms of Notch ligands or truncation mutants (functional agonists or antagonists) can be used in functional assays in tandem with HMJ2-1 to modulate Notch signaling, benchmarking the effect of Jagged2 engagement versus other pathway components.

Supporting context:

• HMJ2-1 is reported for flow cytometry, ELISA, and as a functional agonist to promote Treg cell differentiation, highlighting its use in immunophenotyping and functional assays in combination with various immune or pathway-specific antibodies.
• Studies often cite Jagged1 as a direct comparison protein due to its similarity and overlapping function with Jagged2.

Alternative antibodies to Jagged2 in similar studies include INK3-2 (another anti-Jagged2 clone), and other protein markers relevant to the tissue or disease being studied.

In summary, HMJ2-1 is most commonly used with:

• Antibodies against Notch receptors and other Notch ligands
• Immune cell population markers
• Canonical Notch pathway regulators
• Isotype controls for specificity
• Sometimes, soluble or mutated Notch ligands for pathway modulation

This approach allows comprehensive analysis of Notch pathway activity and cellular context in research settings.

Clone HMJ2-1 refers to a monoclonal antibody that specifically targets Jagged2, a ligand in the Notch signaling pathway, commonly used in studies of the immune system and cell differentiation. Key findings from scientific literature employing HMJ2-1 include:

• Jagged2 Regulation of Immune Responses: HMJ2-1 has been used to demonstrate that Jagged2 regulates important aspects of immune cell function. For example, it was pivotal in showing that dendritic cell-mediated activation of natural killer (NK) cells is controlled by Jagged2, implicating Notch signaling in innate immune responses.

• Role in Transplant Rejection: The HMJ2-1 antibody was instrumental in research showing that Jagged2 signaling promotes IL-6-dependent transplant rejection. Use of HMJ2-1 to block Jagged2 resulted in accelerated allograft rejection, coupled with increased IL-6 and Th2 cytokine production, supporting a role for Jagged2/Notch interactions in T cell-mediated immunity and transplant biology.

• Utility as a Research Tool: HMJ2-1 is described in product literature and research studies as a high-specificity, high-affinity tool for both mouse and human Jagged2, functioning in applications such as flow cytometry (FC) and immunohistochemistry (IHC). It often serves as a blocking antibody to dissect Jagged2 roles in cellular signaling pathways.

• Mechanistic Insights: Findings facilitated by HMJ2-1 have revealed that interference with Jagged2/Notch interactions can significantly influence T cell differentiation, rejection mechanisms, and cytokine milieu, further establishing a link between Notch signaling and immune regulation.

In summary, HMJ2-1 is widely cited as a critical reagent for uncovering the immunological functions of Jagged2 within the Notch pathway, particularly concerning NK cell activation and transplant rejection, and serves as a standard tool in both mouse and human studies.

There is no direct evidence in the provided search results regarding specific dosing regimens for the anti-mouse Jagged 2 antibody clone HMJ2-1 across different mouse models. The available product listings and manufacturer pages do not provide dosing details, nor do general in vivo antibody dosing guides mention HMJ2-1 specifically.

General Guidance on In Vivo Antibody Dosing

While HMJ2-1 is not explicitly covered, dosing regimens for many functional-grade monoclonal antibodies in mice typically involve intraperitoneal administration, with doses commonly ranging from 100 to 500 µg per mouse, given every 2–4 days, depending on the antibody and model. However, these are general guidelines and cannot be assumed to apply to HMJ2-1 without published data.

Steps to Determine Optimal Dosing

• Consult Primary Literature: Peer-reviewed studies using HMJ2-1 in specific mouse models may provide empirically determined doses.
• Contact Manufacturers: Vendors (e.g., Leinco, Creative Diagnostics, Merck Millipore) may have proprietary or unpublished dosing recommendations based on customer feedback or internal testing.
• Pilot Studies: If no published data exist, conduct pilot experiments to establish safety and efficacy, starting with general antibody dosing strategies and adjusting based on observed effects and potential toxicity.

Summary Table of Available Information

Conclusion

The dosing regimen for clone HMJ2-1 in mice is not documented in the available literature or product information. Researchers should seek out peer-reviewed studies, consult antibody vendors for unpublished data, or empirically determine appropriate doses through pilot studies, guided by general principles for in vivo monoclonal antibody administration in mice.